| Title |
Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
|
|---|---|
| Published in |
Drug Design, Development and Therapy, July 2021
|
| DOI | 10.2147/dddt.s281602 |
| Pubmed ID | |
| Authors |
Wajd Alkabbani, John-Michael Gamble |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 3 | 10% |
| Student > Master | 2 | 7% |
| Student > Postgraduate | 2 | 7% |
| Lecturer | 1 | 3% |
| Researcher | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 19 | 66% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Arts and Humanities | 1 | 3% |
| Unspecified | 1 | 3% |
| Nursing and Health Professions | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 18 | 62% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 July 2021.
All research outputs
#15,102,687
of 25,392,582 outputs
Outputs from Drug Design, Development and Therapy
#815
of 2,269 outputs
Outputs of similar age
#215,438
of 453,590 outputs
Outputs of similar age from Drug Design, Development and Therapy
#23
of 59 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,269 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 453,590 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.